Dr Sarah Hayes

Cancer Institute NSW Early Career Fellow
Kolling Institute of Medical Research, Northern Clinical School

Telephone +61 2 9926 4724

Map

Biographical details

Dr Hayes graduated with a BMedSci (Biomedical Sciences, with Distinction) at the University of Western Sydney, from which she was awarded the 2008 Dean's Medal in the School of Biomedical and Health Sciences for overall academic excellence. Following this, Dr Hayes completed a BMedSci with First Class Honours in Medical Sciences (Cancer Research) at Macquarie University, which resulted in a first-author paper in Proteomics Clinical Applications. In 2009, she was awarded an Australian Postgraduate Award and commenced her PhD in the Australian Proteomics Analysis Facility at Macquarie University in the area of colorectal cancer research. In this same year, Dr Hayes was also awarded a Research Scholar Award from the Cancer Institute NSW ($62500/3yrs) to support her work in this area.

Dr Hayes' doctoral research involved the identification and verification of putative plasma protein biomarkers predictive of colorectal cancer patient response to 5-fluorouracil-based chemotherapy using advanced mass spectrometry instrumentation. Dr Hayes is a specialist in targeted mass spectrometry (known as Selected Reaction Monitoring Mass Spectrometry or SRM-MS), as well as in other techniques used in cancer proteomics. During this PhD, Dr Hayes has authored 3 first-author papers, as well as a review article on this research. In addition, she has presented at several national and international conferences including the 2010 American Society of Mass Spectrometry, from which she received a competitively awarded travel grant to attend their annual meeting. She has also given an oral presentation at the annual Australian Proteomics Society Conference in 2012 regarding this research as one of four student talks selected for discussion at this meeting.

Now at the University of Sydney, Dr Hayes has been awarded a Cancer Institute NSW Early Career Fellowship ($599,348/3 yrs) to continue her work using SRM-MS to rapidly screen plasma from non-small cell lung cancer (NSCLC) patients to predict patient response to chemotherapy. This work will greatly contribute to the growing field of research into the personalisation of treatment to individuals, as well as our understanding of the effect of molecular pathogenesis on treatment efficacy.

Selected grants

2014

  • Identification of predictive biomarkers of treatment response in Non-Small Cell Lung Cancer patients; Hayes S; Cancer Institute New South Wales/Early Career Development Fellowship.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Krisp, C., Randall, S., McKay, M., Molloy, M. (2012). Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. Proteomics - Clinical Applications, 6, 42-49. [More Information]
  • Randall, S., McKay, M., Baker, M., Molloy, M. (2010). Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics, 10(10), 2050-2056. [More Information]
  • Chiu, C., Randall, S., Molloy, M. (2009). Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis. Bioanalysis, 1(4), 847-855.

2014

  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]

2012

  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012). Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications, 6(11-12), 626-634. [More Information]
  • Krisp, C., Randall, S., McKay, M., Molloy, M. (2012). Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. Proteomics - Clinical Applications, 6, 42-49. [More Information]

2010

  • Randall, S., McKay, M., Baker, M., Molloy, M. (2010). Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics, 10(10), 2050-2056. [More Information]

2009

  • Chiu, C., Randall, S., Molloy, M. (2009). Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis. Bioanalysis, 1(4), 847-855.

To update your profile click here. For support on your academic profile contact .